Consolidated Statements of Operations - USD ($) shares in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Feb. 29, 2024 |
Feb. 28, 2023 |
Feb. 29, 2024 |
Feb. 28, 2023 |
|
| Operating expenses: | ||||
| General and administrative | $ 2,757,000 | $ 2,971,000 | $ 7,756,000 | $ 14,347,000 |
| Research and development | 650,000 | 938,000 | 3,643,000 | 1,651,000 |
| Amortization and depreciation | 7,000 | 12,000 | 25,000 | 165,000 |
| Inventory charge | 20,633,000 | |||
| Total operating expenses | 3,414,000 | 3,921,000 | 11,424,000 | 36,796,000 |
| Operating loss | (3,414,000) | (3,921,000) | (11,424,000) | (36,796,000) |
| Interest and other expenses: | ||||
| Interest on convertible notes | (1,151,000) | (1,142,000) | (3,512,000) | (3,447,000) |
| Amortization of discount on convertible notes | (409,000) | (565,000) | (951,000) | (1,721,000) |
| Amortization of debt issuance costs | (203,000) | (17,000) | (572,000) | (51,000) |
| Issuance costs for private placement of shares and warrants through placement agent (Note 5) | (906,000) | |||
| Loss on induced conversion | (3,353,000) | (2,018,000) | (5,993,000) | (2,656,000) |
| Finance charges | (882,000) | (5,884,000) | (2,685,000) | (7,761,000) |
| Loss on note extinguishment | (1,550,000) | (6,040,000) | ||
| Loss on derivatives | (958,000) | (155,000) | (971,000) | (8,756,000) |
| Total interest and other expenses | (8,506,000) | (9,781,000) | (21,630,000) | (24,392,000) |
| Loss before income taxes | (11,920,000) | (13,702,000) | (33,054,000) | (61,188,000) |
| Income tax benefit | 0 | 0 | 0 | 0 |
| Net loss | $ (11,920,000) | $ (13,702,000) | $ (33,054,000) | $ (61,188,000) |
| Weighted average common shares outstanding, Basic | 982,209 | 832,215 | 954,814 | 810,986 |
| Weighted average common shares outstanding, Diluted | 982,209 | 832,215 | 954,814 | 810,986 |
| Loss per share, Basic | $ (0.01) | $ (0.02) | $ (0.04) | $ (0.08) |
| Loss per share, Diluted | $ (0.01) | $ (0.02) | $ (0.04) | $ (0.08) |
| X | ||||||||||
- Definition Finance charges related to interest expense. No definition available.
|
| X | ||||||||||
- Definition The amount of gain (loss) incurred on derivatives. No definition available.
|
| X | ||||||||||
- Definition Amount of issuance costs for private placement of shares and warrants operating activities. No definition available.
|
| X | ||||||||||
- Definition The amount of loss on induced conversion of debt. No definition available.
|
| X | ||||||||||
- Definition Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of amortization expense attributable to debt issuance costs. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Interest and debt related expenses associated with nonoperating financing activities of the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|